Trump announces 100% chip tariff as Apple ups U.S. investment
Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported second quarter EPS of $1.46, $0.40 better than the analyst estimate of $1.06. Revenue for the quarter came in at $12.27B versus the consensus estimate of $11.34B.
Guidance
Bristol-Myers Squibb sees FY 2025 EPS of $6.35-$6.65 versus the analyst consensus of $6.32.
Bristol-Myers Squibb sees FY 2025 revenue of $46.50B-$47.50B versus the analyst consensus of $46.27B.
Bristol-Myers Squibb’s stock price closed at $45.98. It is down -9.08% in the last 3 months and down -4.55% in the last 12 months.
Bristol-Myers Squibb saw 0 positive EPS revisions and 17 negative EPS revisions in the last 90 days. See Bristol-Myers Squibb’s stock price’s past reactions to earnings here.
According to InvestingPro, Bristol-Myers Squibb’s Financial Health score is "good performance".
Check out Bristol-Myers Squibb’s recent earnings performance, and Bristol-Myers Squibb’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar